Xilong Scientific Co., Ltd.
002584.SZ · SHZ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 6.18B | 426.78M | 104.39M | 89.06M | 0.15 |
| 2023 FY | 7.09B | 459.70M | 46.01M | 33.35M | 0.06 |
| 2024 FY | 7.82B | 522.88M | 93.16M | 61.77M | 0.11 |
| 2025 FY | 7.33B | 521.67M | 64.06M | -75.49M | -0.13 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 4.98B | 2.66B | 691.01M | 1.05B | 2.31B |
| 2023 FY | 4.77B | 2.41B | 559.89M | 1.01B | 2.35B |
| 2024 FY | 4.72B | 2.41B | 593.21M | 910.74M | 2.30B |
| 2025 FY | 4.91B | 2.73B | 709.77M | 1.12B | 2.17B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -190.88M | -323.71M | -514.59M | -43.52M | -190.03M |
| 2023 FY | -284.71M | -215.25M | -499.96M | -11.70M | -179.62M |
| 2024 FY | 302.16M | -44.94M | 257.23M | -83.27M | 28.53M |
| 2025 FY | 69.36M | -100.12M | -30.75M | -47.80M | 138.83M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2023 FY | 5.99B | 6.44B | — | — | — |
| 2024 FY | 4.04B | 4.36B | — | — | — |
| 2025 FY | 5.35B | 5.75B | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 1.64B | 110.05M | 41.11M | -83.96M | -0.27 |
| 2025 Q3 | 1.96B | 154.51M | 12.94M | 13.49M | 0.02 |
| 2025 Q4 | 2.01B | 121.40M | 771.93K | -13.66M | -0.02 |
| 2026 Q1 | 1.82B | 160.50M | 19.93M | 11.98M | 0.02 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 5.01B | 2.78B | 738.40M | 952.90M | 2.22B |
| 2025 Q3 | 5.14B | 2.90B | 738.91M | 1.53B | 2.24B |
| 2025 Q4 | 4.91B | 2.73B | 709.77M | 1.12B | 2.17B |
| 2026 Q1 | 5.12B | 2.93B | 529.97M | 1.19B | 2.19B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | 85.98M | -16.95M | 69.03M | -12.49M | 108.82M |
| 2025 Q3 | -17.73M | -14.55M | -32.28M | — | 505.73K |
| 2025 Q4 | -78.30M | -55.59M | -133.89M | -13.35M | 97.16M |
| 2026 Q1 | -229.27M | -17.43M | -246.71M | -12.64M | -80.93M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 3.03B | 3.24B | — | — | — |
| 2025 Q3 | 5.21B | 6.00B | — | — | — |
| 2025 Q4 | 5.43B | 5.84B | — | — | — |
| 2026 Q1 | 4.67B | 5.33B | — | — | — |